PTBP1-RNA-Binding Inhibitor P6 TFA is a peptide designed to disrupt PTBP1-mediated RNA recognition through competitive binding. Its aromatic and charged residues mimic key RNA-contacting motifs. Researchers examine its conformational preferences and affinity profiles. Applications include RNA-protein interaction studies, inhibitor screening, and motif engineering.
CAT No: R2833
PTBP1-RNA-binding inhibitor P6 TFA is a specialized small molecule compound designed to selectively modulate the activity of polypyrimidine tract-binding protein 1 (PTBP1), a critical RNA-binding protein involved in pre-mRNA splicing regulation and post-transcriptional gene expression. Characterized by its ability to interfere with RNA-protein interactions, this inhibitor provides researchers with a valuable tool for dissecting the functional roles of PTBP1 in various cellular processes. Its trifluoroacetate (TFA) salt form ensures enhanced solubility and stability, making it suitable for a range of in vitro and cellular assays. The molecular design of P6 TFA is optimized to disrupt PTBP1's binding affinity for specific RNA motifs, thereby enabling targeted studies on alternative splicing and RNA metabolism. By offering a means to precisely inhibit PTBP1, this compound supports advanced research into gene regulatory networks, RNA processing events, and the broader landscape of RNA biology.
Alternative Splicing Research: PTBP1-RNA-binding inhibitor P6 TFA is widely employed in the study of alternative splicing mechanisms, as PTBP1 is a known regulator of exon inclusion and exclusion in pre-mRNA transcripts. By selectively inhibiting PTBP1, researchers can investigate the downstream effects on splice site selection and exon definition, facilitating the mapping of alternative splicing events across different genes. This application is particularly valuable for elucidating the splicing code and understanding how PTBP1 contributes to transcriptome diversity in various biological contexts.
Gene Expression Modulation: In studies focused on post-transcriptional regulation, P6 TFA serves as a strategic tool to probe the influence of PTBP1 on mRNA stability, localization, and translation efficiency. By disrupting PTBP1's interaction with target transcripts, scientists can assess changes in mRNA abundance and protein output, revealing the multifaceted roles of this RNA-binding protein in controlling gene expression. This approach is instrumental for exploring gene regulatory networks and identifying potential nodes of intervention in cellular signaling pathways.
Neurobiology and Neuronal Differentiation: The inhibitor is also leveraged in neurobiology research, where PTBP1 plays a pivotal role in neuronal development and differentiation. By modulating PTBP1 activity with P6 TFA, investigators can study its impact on neuronal precursor cell fate decisions, axon guidance, and synaptic function. This application is crucial for unraveling the molecular basis of neural circuit formation and for understanding the contribution of RNA-binding proteins to neurodevelopmental processes.
Cancer Biology and Tumorigenesis: Research in oncology has highlighted the involvement of PTBP1 in cancer cell proliferation, migration, and invasion. Utilizing P6 TFA, scientists can interrogate the consequences of PTBP1 inhibition on tumor cell behavior, including alterations in splicing patterns, changes in cell cycle progression, and modulation of oncogenic pathways. This application supports efforts to delineate the molecular mechanisms underlying tumorigenesis and to identify novel therapeutic targets within the RNA processing machinery.
High-Throughput Screening and Drug Discovery: P6 TFA is an enabling reagent in high-throughput screening platforms designed to identify modulators of RNA-protein interactions. Its use in assay development allows for the systematic evaluation of compound libraries for activity against PTBP1 or related RNA-binding proteins. This application accelerates the discovery of new chemical probes and potential lead compounds for further investigation in RNA-targeted drug development.
PTBP1-RNA-binding inhibitor P6 TFA represents a versatile and scientifically robust tool for advancing research across molecular biology, functional genomics, and chemical biology disciplines. Its ability to specifically disrupt PTBP1-mediated RNA interactions provides unique insights into RNA processing, gene regulation, and cellular differentiation. Whether applied to fundamental studies of alternative splicing or leveraged in drug discovery initiatives, P6 TFA empowers researchers to unravel the complexities of RNA-protein networks and to explore innovative approaches for modulating gene expression at the post-transcriptional level.
1. TMEM16F and dynamins control expansive plasma membrane reservoirs
5. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More